Camblong Jurgi 4

What Happened

• Jurgi Camblong, CEO of SOPHiA GENETICS SA (SOPH), exercised 31,940 stock options and sold shares across multiple transactions on June 25–26, 2026.
• He exercised 31,940 options at $3.16 per share (cash paid $100,930) and sold those 31,940 shares at a weighted average of $5.84 for proceeds of $186,395. In addition he sold 18,129 shares at a weighted average of $5.73 for $103,934 and 1,373 shares at $5.70 for $7,826. Total shares sold = 51,442; total proceeds from sales ≈ $298,155.
• The activity includes an acquisition (option exercise) and multiple sales; sales are often routine disposition of previously granted equity and are not by themselves a definitive signal of sentiment.

Key Details

• Transaction dates: 2026-06-25 (1,373 shares sold) and 2026-06-26 (other exercises/sales). Filing date: 2026-06-29 (Form 4).
• Prices/ranges: 1,373 @ $5.70; 18,129 @ weighted avg $5.73 (range $5.70–$5.78); 31,940 @ weighted avg $5.84 (range $5.80–$5.94). Exercise price: $3.16 for the 31,940 options exercised.
• Shares owned after transaction (derivative holdings): holds 4,709,536 outstanding stock options across remaining grant tranches (per filing).
• Footnotes of note: F1 indicates at least some trades were made pursuant to a Rule 10b5-1 trading plan; F4 confirms the options were fully vested; F2/F3 note weighted-average sale prices and provide price ranges.
• Timeliness: Filed on 2026-06-29; the Form 4 reports transactions from 6/25–6/26 and was filed promptly (not indicated as late).

Context

• This appears to be a typical option exercise followed by sales (a cashless-type outcome): options were exercised at $3.16 and those shares were sold at higher market prices, generating net proceeds.
• The CEO still holds a large options position (4.7M+ options), meaning further exercises or sales are possible in the future.
• The filing is factual disclosure of insider activity; it does not by itself explain motivations.